We Know More About Those Covid 19 VARIANTS 2021

The case was registered on January 26, 2012. If we

usually have new cases of COVID-19 virus or

disease, you can find it in the playlist in detail. A few

weeks ago we told you about the double strain of

the rapidly spreading COVID-19 virus.

We Know More About

Those Covid 19

VARIANTS 2021

Well, scientists have worked hard, and now we

know more about it. The news is not good. But

behind the complex headings are some interesting

and straightforward explanations that help us shed

light on what we really know. First: On January 22,

the US government released a short-term

preliminary report from NERVTAG’s Virus Risk

Advisory Group stating that the new strains are

more deadly.

 

The report examines independent analyzes of

COVID-19 and deaths from research universities in

the UK for public health. Everyone looks at type

B.1.1.7, or something called “American type

 

It was first found in the United States in September

but has since spread to at least 60 countries and 24

states. Models also indicate that the highly portable

transmission will dominate the United States in

March. At first glance, B 1.1.7 does not make

people sick. But these new analyzes cover COVID-

19 issues independently from November 2020 to

January 2021.

 

And everyone has found that 1.1.1.7 people are

more likely to die, regardless of the cause. Thus

Norwitag concluded that there was a “real

possibility” associated with such an increase in

deaths.

However, there are restrictions on this port. Perhaps

in particular, comprehensive studies tested 8% of

coronavirus-related deaths that occurred at that

time. This is a small sample, so it may not

represent a large population of England, let alone

the world. There are also delays in getting people

diagnosed with opioids, when they are tested and

when we know what is happening to them.

 

It is important to analyze the data and make quick

decisions. An additional B.1.1.7 infection has led to

a significant decrease in COVID-19 cases in the

United States this winter. Many experts say that

there is a high mortality rate for B.1.1.7 before we

can determine if we need to do research. In

contrast, another preliminary report released this

week suggests that biotech vaccines may provide

such protection.

 

This is good news! But … there is bad news about

vaccines. The last two editions indicate that some

other variants may be somewhat effective for

existing vaccines. Now both studies are small and

need to be revisited. It was common for information

to be shared quickly during the first disease

research study, but this meant that these subjects

were not an important part of the scientific process

and any findings should be carefully considered.

 

The ultimate way is for health experts to say that

these vaccines will work and of course they are

valuable. What these studies show is that such

changes can pose more immediate challenges than

most scientists. In addition, it is possible for people

infected with a previous version of the virus to

reactivate it with a new strain.

 

The first edition, uploaded January 19, looked at

B.1.351, and for the first time in South Africa, an

additional versatile anti-virus interaction was found.

You may have mentioned the “South African type

Researchers especially want to see the immune

response to COVID-19 to protect people from the

new version of the virus. Thus, they took serum

samples from 44 people in the previous circuits of

the Sars Covey 2. Unfortunately, 21 of them failed to

stop B.1.351. This indicates that people recovering

from COVID-19 may still have this type, and it may

slow down, as reported in Brazil.

 

Blood samples were found to contain a large

number of organs. It may be indicated that people

with myocardial infarction are at risk of flushing

because people produce somewhat more

antibodies after their illness. When people receive

even two doses of a biotech or CT vaccine, their

bodies naturally produce more unstable antibodies

against infected people.

 

Thus, the vaccine may be more protective against

relatively small infections. The second article, also

uploaded on January 19, notes that there are limits,

too, because not all fluctuations are the same. In

this study, researchers pulled the neutral bodies of

20 people who received a dose of either modern or

biotech vaccines.

 

They then examined how effective the microbodies

were against mutations found in the virus from

South Africa and Brazil, and some antibodies were

effective only in these mutations. But some were

injured, only a third of them. Although vaccines

against the original SARS Covey 2 virus are close to

95%, they may not be effective against new strains.

However, experts insist that these vaccines are

worth getting!

 

Remember that the US FDA and said that they

confirm that any vaccine shows a reduction of 50 in

50 cases, because it really is a big difference that

made a difference. The researchers said that these

vaccines are still expected to provide a high level of

protection against particularly dangerous diseases.

 

But statistics show that it can discourage people

from doing less or less symbolic things. Although

they will kill people, it is rare that they all want to

reduce the spread of the virus themselves.

Fortunately, if needed, the vaccine can be adapted

to a new species within a few weeks.

 

In fact, on January 25, Moderna announced that

another vaccine that could be used as a shotgun to

protect against mutations should be developed in

South Africa. Most importantly, health experts say

that we are vaccinating people faster while

vaccines are more effective, and as long as we

follow other health guidelines and

recommendations we can eradicate this disease as

soon as possible. Are Thanks for watching this

episode of Sex Show!

 

 

Add a Comment

Your email address will not be published. Required fields are marked *